Hernàn Picard

2.8k total citations · 2 hit papers
39 papers, 2.0k citations indexed

About

Hernàn Picard is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Neurology. According to data from OpenAlex, Hernàn Picard has authored 39 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Psychiatry and Mental health, 12 papers in Pathology and Forensic Medicine and 6 papers in Neurology. Recurrent topics in Hernàn Picard's work include Migraine and Headache Studies (25 papers), Trigeminal Neuralgia and Treatments (11 papers) and Psychosomatic Disorders and Their Treatments (8 papers). Hernàn Picard is often cited by papers focused on Migraine and Headache Studies (25 papers), Trigeminal Neuralgia and Treatments (11 papers) and Psychosomatic Disorders and Their Treatments (8 papers). Hernàn Picard collaborates with scholars based in United States, Germany and Switzerland. Hernàn Picard's co-authors include Daniel D. Mikol, Robert Lenz, Feng Zhang, Uwe Reuter, Gregor Broessner, Jo Bonner, Peter J. Goadsby, Yngve Hallström, Sandhya Sapra and Messoud Ashina and has published in prestigious journals such as New England Journal of Medicine, Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Hernàn Picard

37 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Controlled Trial of Erenumab for Episodic Migraine

2017 631 citations Peter J. Goadsby, Uwe Reuter et al. New England Journal of Medicine profile →
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

2018 423 citations David W. Dodick, Messoud Ashina et al. profile →

Peers

Countries citing papers authored by Hernàn Picard

Since Specialization

Citations

This map shows the geographic impact of Hernàn Picard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hernàn Picard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hernàn Picard more than expected).

Fields of papers citing papers by Hernàn Picard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hernàn Picard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hernàn Picard. The network helps show where Hernàn Picard may publish in the future.

Co-authorship network of co-authors of Hernàn Picard

This figure shows the co-authorship network connecting the top 25 collaborators of Hernàn Picard. A scholar is included among the top collaborators of Hernàn Picard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hernàn Picard. Hernàn Picard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: Results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial 2023 ·Journal of the American Academy of Dermatology ·Joseph F. Merola, Lawrence Charles Parish, Lyn Guenther, Charles Lynde, J.‐P. Lacour, Petra Staubach, Sue Cheng, Maria Paris, Hernàn Picard, (unknown), (unknown), Mindy Chen, Kim Papp	13
2	Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet’s Syndrome 2023 ·American Journal of Clinical Dermatology ·Philip J. Mease, Gülen Hatemi, Maria Paris, Sue Cheng, Peter Maes, Wendy Zhang, Rebecca Shi, (unknown), Hernàn Picard, Linda Stein Gold	25
3	Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials 2021 ·The Journal of Headache and Pain ·Stewart J. Tepper, Messoud Ashina, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo Bonner, Hernàn Picard, Sunfa Cheng, Denise E. Chou, (unknown), Jan Klatt, Daniel D. Mikol	11
4	Migraine Polygenic Risk Score Is Associated with Severity of Migraine – Analysis of Genotypic Data from Four Placebo-controlled Trials of Erenumab (1214) 2020 ·Neurology ·Daniel D. Mikol, Hernàn Picard, Jan Klatt, Andrea Wang, (unknown), Hreinn Stefánsson	1
5	Efficacy and safety of erenumab in women with a history of menstrual migraine 2020 ·The Journal of Headache and Pain ·Jelena Pavlović, Koen Paemeleire, Hartmut Göbel, Jo Bonner, Alan M. Rapoport, Risa Kagan, Feng Zhang, Hernàn Picard, Daniel D. Mikol	30
6	Long-term efficacy of erenumab in patients with episodic migraine who have failed prior preventive migraine therapies 2019 ·European Journal of Neurology ·Uwe Reuter, Todd J. Schwedt, David Kudrow, Koen Paemeleire, (unknown), Jan Klatt, Hernàn Picard, Denise E. Chou, (unknown)	2
7	Sustained Efficacy Over 1 Year of Treatment With Erenumab: Results From the Extension Phase of the STRIVE Study in Episodic Migraine (S38.005) 2019 ·Neurology ·Denise E. Chou, Peter J. Goadsby, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo Bonner, Feng Zhang, Sandhya Sapra, Jan Klatt, Hernàn Picard, Daniel D. Mikol	3
8	Erenumab Immunogenicity: a Pooled Analysis of Phase 2 and Phase 3 Migraine Prevention Clinical Trials (P4.098) 2018 ·Neurology ·Bert B. Vargas, Amaal J. Starling, Stephen D. Silberstein, Yanchen Zhou, Marie‐Louise Trotman, Fei Xue, (unknown), Hernàn Picard, Daniel D. Mikol	5
9	Efficacy of Erenumab For the Treatment of Patients with Episodic Migraine with Aura (P4.094) 2018 ·Neurology ·Peter McAllister, (unknown), (unknown), Lawrence C. Newman, Cristina Tassorelli, Feng Zhang, Hernàn Picard, Daniel D. Mikol	3
10	Erenumab Safety Among Migraine Patients Using Triptans or With Cardiovascular (CV) Risk Factors (P4.100) 2018 ·Neurology ·Paul Winner, Uwe Reuter, David W. Dodick, David Kudrow, J Rózniecki, Fei Xue, (unknown), Sunfa Cheng, Hernàn Picard, Daniel D. Mikol	1
11	Early onset of efficacy with erenumab in patients with episodic and chronic migraine 2018 ·The Journal of Headache and Pain ·Todd J. Schwedt, Uwe Reuter, Stewart J. Tepper, Messoud Ashina, David Kudrow, Gregor Broessner, Guy Boudreau, Peter McAllister, Thuy Vu, (unknown), Sunfa Cheng, Hernàn Picard, Shihua Wen, Joseph M. Kahn, Jan Klatt, Daniel D. Mikol	72
12	Efficacy of erenumab in subjects with episodic migraine with prior preventive treatment failure(s) 2017 ·Ghent University Academic Bibliography (Ghent University) ·Peter J. Goadsby, Koen Paemeleire, Gregor Broessner, Jan Lewis Brandes, Jan Klatt, Feng Zhang, Hernàn Picard, Daniel D. Mikol, Robert Lenz	8
13	A Controlled Trial of Erenumab for Episodic Migraine breakdown → 2017 ·New England Journal of Medicine ·Peter J. Goadsby, Uwe Reuter, Yngve Hallström, Gregor Broessner, Jo Bonner, Feng Zhang, Sandhya Sapra, Hernàn Picard, Daniel D. Mikol, Robert Lenz	631
14	Depression symptom clusters and their predictive value for treatment outcomes: Results from an individual patient data meta-analysis of duloxetine trials 2014 ·Journal of Psychiatric Research ·Alexander Schacht, Philip Gorwood, Philip Boyce, Ayal Schaffer, Hernàn Picard	15
15	Early vs. conventional switching of antidepressants in patients with MDD and moderate to severe pain: A double-blind randomized study 2012 ·Journal of Affective Disorders ·Irene Romera, Víctor Pérez, José M. Menchón, Alexander Schacht, (unknown), (unknown), Mocrane Abbar, Hernàn Picard, Inmaculada Gilaberte	19
16	Impaired saccadic adaptation in schizophrenic patients with high neurological soft sign scores 2012 ·Psychiatry Research ·Hernàn Picard, (unknown), Isabelle Amado, Raphaël Gaillard, Marie‐Odile Krebs, Cécile Beauvillain	12
17	Résultats de la cohorte française de l’étude observationnelle européenne FINDER : qualité de vie de patients traités par antidépresseurs 2012 ·L Encéphale ·N. Dantchev, Stéphanie Tcherny‐Lessenot, Hernàn Picard, (unknown), Deborah Quail	0
18	Changer d’antidépresseur : quand, comment, pourquoi ? 2011 ·L Encéphale ·D. Gourion, (unknown), (unknown), Hernàn Picard	2
19	Correlates between neurological soft signs and saccadic parameters in schizophrenia 2009 ·Progress in Neuro-Psychopharmacology and Biological Psychiatry ·Hernàn Picard, Isabelle Amado, Marie‐Chantal Bourdel, Steffen Landgraf, Jean‐Pierre Olié, Marie‐Odile Krebs	13
20	The Role of the Cerebellum in Schizophrenia: an Update of Clinical, Cognitive, and Functional Evidences 2007 ·Schizophrenia Bulletin ·Hernàn Picard, I. Amado, Sabine Mouchet-Mages, J.-P. Olié, Marie‐Odile Krebs	217

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact